keyword
MENU ▼
Read by QxMD icon Read
search

Ipilimumab

keyword
https://www.readbyqxmd.com/read/28324889/evaluation-of-clinicopathological-factors-in-pd-1-response-derivation-and-validation-of-a-prediction-scale-for-response-to-pd-1-monotherapy
#1
Adi Nosrati, Katy K Tsai, Simone M Goldinger, Paul Tumeh, Barbara Grimes, Kimberly Loo, Alain P Algazi, Thi Dan Linh Nguyen-Kim, Mitchell Levesque, Reinhard Dummer, Omid Hamid, Adil Daud
BACKGROUND: Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma. We developed and validated a clinical prediction scale for response to anti- PD-1 monotherapy. METHODS: A total of 315 patients with advanced melanoma treated with pembrolizumab (2 or 10 mg kg(-1) Q2W or Q3W) or nivolumab (3 mg kg(-1) Q2W) at four cancer centres between 2011 to 2013 served as the setting for the present cohort study. Variables with significant association to response on a univariate analysis were entered into a forward stepwise logistic regression model and were given a score based on ORs to calculate a clinical prediction scale...
March 21, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28324885/reply-to-comment-on-efficacy-and-toxicity-of-treatment-with-the-anti-ctla-4-antibody-ipilimumab-in-patients-with-metastatic-melanoma-after-prior-anti-pd-1-therapy
#2
Samantha Bowyer, Prashanth Prithviraj, Paul Lorigan, James Larkin, Grant McArthur, Victoria Atkinson, Michael Millward, Muoi Khou, Stefan Diem, Sangeetha Ramanujam, Ben Kong, Elizabeth Liniker, Alexander Guminski, Phillip Parente, Miles C Andrews, Sagun Parakh, Jonathan Cebon, Georgina V Long, Matteo S Carlino, Oliver Klein
No abstract text is available yet for this article.
March 21, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28324884/comment-on-efficacy-and-toxicity-of-treatment-with-the-anti-ctla-4-antibody-ipilimumab-in-patients-with-metastatic-melanoma-after-prior-anti-pd-1-therapy
#3
Keisuke Imafuku, Koji Yoshino, Kei Yamaguchi, Satoshi Tsuboi, Kuniaki Ohara, Hiroo Hata
No abstract text is available yet for this article.
March 21, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28323658/changing-face-of-metastatic-prostate-cancer-the-law-of-diminishing-returns-holds-true
#4
Ulka N Vaishampayan
PURPOSE OF REVIEW: Prostate cancer presents with a multitude of faces. It ranges from localized cancers staying quiescent for many years during active surveillance to the raging diffuse liver metastases causing terminal disease. The incidence of metastatic disease is increasing. This review will highlight some of the recent developments as well as ongoing challenges of managing advanced prostate cancer. RECENT FINDINGS: Significant strides are being made in managing metastatic prostate cancer...
March 18, 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28323504/pembrolizumab-use-for-the-treatment-of-advanced-melanoma
#5
Pol Specenier
Until recently, overall long term survival in patients with stage IV melanoma was lower than 10 %. However, the treatment of melanoma has evolved rapidly over the last few years, with the advent of inhibitors of BRAF and MEK and of immunotherapeutic agents including ipilimumab, nivolumab, and pembrolizumab. Areas covered: This is a comprehensive review of the literature on the role of pembrolizumab in melanoma. Pembrolizumab is a Programmed Death Receptor 1 (PD-1) directed monoclonal antibody which is approved by FDA and EMA for the treatment of patients with metastatic melanoma...
March 21, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28316007/talimogene-laherparepvec-for-treating-metastatic-melanoma-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#6
REVIEW
Nigel Fleeman, Adrian Bagust, Angela Boland, Sophie Beale, Marty Richardson, Ashma Krishan, Angela Stainthorpe, Ahmed Abdulla, Eleanor Kotas, Lindsay Banks, Miranda Payne
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Amgen) of talimogene laherparepvec (T-VEC) to submit clinical and cost-effectiveness evidence for previously untreated advanced (unresectable or metastatic) melanoma as part of the Institute's Single Technology Appraisal process. The Liverpool Reviews and Implementation Group (LRiG) at the University of Liverpool was commissioned to act as the Evidence Review Group (ERG). This article presents a summary of the company's submission of T-VEC, the ERG review and the resulting NICE guidance (TA410), issued in September 2016...
March 18, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28315636/pembrolizumab-for-metastatic-melanoma-in-a-renal-allograft-recipient-with-subsequent-graft-rejection-and-treatment-response-failure-a-case-report
#7
Vineet Kwatra, Narayan V Karanth, Kelum Priyadarshana, Michail Charakidis
BACKGROUND: Transplant patients were excluded from the pivotal phase III trials of checkpoint inhibitors in metastatic melanoma. The efficacy and toxicity profiles of checkpoint inhibitors in this cohort of patients are not well described. To the best of our knowledge, this is the first case report of a renal transplant patient with stage IV melanoma treated with a programmed cell death protein 1 checkpoint inhibitor that led to both treatment failure and renal graft rejection. CASE PRESENTATION: We present a case of a 58-year-old white man with a long-standing cadaveric renal transplant who was diagnosed with a B-Raf Proto-Oncogene, Serine/Threonine Kinase wild-type metastatic melanoma...
March 19, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28303522/nanotechnology-for-the-treatment-of-melanoma-skin-cancer
#8
REVIEW
Lucas B Naves, Chetna Dhand, Jayarama Reddy Venugopal, Lakshminarayanan Rajamani, Seeram Ramakrishna, Luis Almeida
Melanoma is the most aggressive type of skin cancer and has very high rates of mortality. An early stage melanoma can be surgically removed, with a survival rate of 99%. This literature review intends to elucidate the possibilities to treat melanoma skin cancer using hybrid nanofibers developed by advanced electrospinning process. In this review we have shown that the enhanced permeability and retention is the basis for using nanotechnology, aiming topical drug delivery. The importance of the detection of skin cancer in the early stages is directly related to non-metastatic effects and survival rates of melanoma cells...
March 16, 2017: Progress in biomaterials
https://www.readbyqxmd.com/read/28303311/-immunotherapy-of-cancer-with-checkpoint-inhibitors-not-only-in-malignant-melanoma
#9
A Neubauer
The newest weapon in cancer therapy is checkpoint inhibition, which is the result of basic immunology research. The success of this therapy is based on the fact that upon light microscopy, many solid tumors harbor lymphocytic cells infiltrating the tumor (TILs), and in many solid tumors, the presence of these TILs are prognostic. Ipilimumab was the first monoclonal antibody developed against a target present on T cells after becoming activated, CTLA-4. In malignant melanoma, ipilimumab showed its beneficial effect as compared to a placebo peptide...
March 16, 2017: Der Internist
https://www.readbyqxmd.com/read/28302128/news-from-the-melanoma-sessions-of-the-european-cancer-congress-2017
#10
EDITORIAL
Piotr Rutkowski, Katarzyna Kozak
During the European Cancer Congress, the melanoma sessions focused on practice changing trials. Recent developments and approvals in immunotherapy and targeted agents have significantly changed the landscape of melanoma therapy in the metastatic setting and provide great promise for adjuvant and neoadjuvant treatment in high-risk locoregional disease. Perioperative (combined pre- and postoperative) strategies may be extremely beneficial for patients with bulky stage IIIC disease. The long-term results of the European Organisation for Research and Treatment of Cancer (EORTC) 18071 adjuvant trial ipilimumab versus placebo after complete resection of high-risk stage III melanoma, demonstrating improvement in overall survival, has established the reference bar for further trials with postoperative therapy...
March 17, 2017: BMC Medicine
https://www.readbyqxmd.com/read/28299199/advances-in-understanding-hypopituitarism
#11
REVIEW
Mareike R Stieg, Ulrich Renner, Günter K Stalla, Anna Kopczak
The understanding of hypopituitarism has increased over the last three years. This review provides an overview of the most important recent findings. Most of the recent research in hypopituitarism has focused on genetics. New diagnostic techniques like next-generation sequencing have led to the description of different genetic mutations causative for congenital dysfunction of the pituitary gland while new molecular mechanisms underlying pituitary ontogenesis have also been described. Furthermore, hypopituitarism may occur because of an impairment of the distinctive vascularization of the pituitary gland, especially by disruption of the long vessel connection between the hypothalamus and the pituitary...
2017: F1000Research
https://www.readbyqxmd.com/read/28295542/unexpected-recalcitrant-course-of-drug-induced-erythema-multiforme-like-eruption-and-interstitial-pneumonia-sequentially-occurring-after-nivolumab-therapy
#12
Hisashi Nomura, Hayato Takahashi, Satsuki Suzuki, Yuichi Kurihara, Shotaro Chubachi, Ichiro Kawada, Hiroyuki Yasuda, Tomoko Betsuyaku, Masayuki Amagai, Takeru Funakoshi
Vemurafenib improves survival of melanoma patients. However, cutaneous side-effects commonly occur in them. Nivolumab and ipilimumab are monoclonal antibodies against programmed death 1 and cytotoxic T-lymphocyte-associated antigen 4, both of which regulate excessive T-cell activation. Although these agents induce antitumor immunity against melanoma, the modified immune condition may result in an unexpected adverse reaction which has not been observed previously. Herein, we report a case who manifested severe erythema multiforme-like eruption with mucosal involvement associated with vemurafenib following nivolumab...
March 11, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28292987/-management-of-toxicities-of-immune-checkpoint-inhibitors
#13
Yoshitsugu Horio
Immune checkpoint inhibitors, including the anti-CTLA-4 antibody ipilimumab, the anti-PD-1 antibodies nivolumab and pembrolizumab, and the anti-PD-L1 antibody atezolizumab had produced long-lasting tumor responses in several malignancies. Immune-related Adverse Events(irAEs)which are different from adverse events of conventional chemotherapy and molecular targeted therapy, occur as a consequence of impaired self-tolerance from loss of T-cell inhibition. The main irAEs of immune checkpoint inhibitors include dermatological, gastrointestinal, pulmonary, hepatic, endocrine, renal toxicities...
March 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28286925/cabozantinib-for-renal-cell-carcinoma-current-and-future-paradigms
#14
REVIEW
Ahmed Abdelaziz, Ulka Vaishampayan
Cabozantinib was approved by the FDA in April 2016 for the treatment of advanced renal cancer, pretreated with at least one prior antiangiogenic therapy. This is the first agent in the therapy of kidney cancer to show a statistically significant improvement in all three endpoints of clinical efficacy, response rate, progression free survival, and overall survival (OS), in a phase III randomized trial. The reporting of METEOR coincided with that of the Checkmate 025 study which randomized similarly eligible patients to receive nivolumab or everolimus 10 mg daily...
March 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28285682/pretreatment-neutrophil-to-lymphocyte-ratio-as-a-marker-of-outcomes-in-nivolumab-treated-patients-with-advanced-non-small-cell-lung-cancer
#15
Stephen J Bagley, Shawn Kothari, Charu Aggarwal, Joshua M Bauml, Evan W Alley, Tracey L Evans, John A Kosteva, Christine A Ciunci, Peter E Gabriel, Jeffrey C Thompson, Susan Stonehouse-Lee, Victoria E Sherry, Elizabeth Gilbert, Beth Eaby-Sandy, Faith Mutale, Gloria DiLullo, Roger B Cohen, Anil Vachani, Corey J Langer
OBJECTIVES: Efficient use of nivolumab in non-small-cell lung cancer (NSCLC) has been limited by the lack of a definitive predictive biomarker. In patients with metastatic melanoma treated with ipilimumab, a pretreatment neutrophil-to-lymphocyte ratio (NLR)<5 has been associated with improved survival. This retrospective cohort study aimed to determine whether the pretreatment NLR was associated with outcomes in NSCLC patients treated with nivolumab. METHODS: We reviewed the medical records of all patients with previously treated advanced NSCLC who received nivolumab between March 2015 and March 2016 outside of a clinical trial at the University of Pennsylvania...
April 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28277102/immune-related-ocular-toxicities-in-solid-tumor-patients-treated-with-immune-checkpoint-inhibitors-a-systematic-review
#16
Omar Abdel-Rahman, Hani Oweira, Ulf Petrausch, Daniel Helbling, Jan Schmidt, Meinrad Mannhart, Arianeb Mehrabi, Othmar Schöb, Anwar Giryes
Immune-related ocular toxicities are uncommon but serious adverse events that may be associated with the use of immune checkpoint inhibitors. The objective of this review is to assess the incidence and risk of ocular toxicities which are potentially immune-related and occur with immune checkpoint treatment of solid tumors. Areas covered: PubMed database has been searched till June 2016. Prospective clinical trials reporting the occurrence of immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors were included...
February 24, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28276859/meta-analysis-of-randomized-controlled-trials-for-the-incidence-and-risk-of-fatal-adverse-events-in-cancer-patients-treated-with-ipilimumab
#17
Jianhong Zhu, Junyan Wu, Guocheng Li, Jianfang Li, Yin Lin, Zhichao He, Chen Su, Wenxia Zhao, Qianqian Wu, Zepeng Chen, Kaifeng Qiu
BACKGROUND: Ipilimumab is a fully human immunoglobulin G1 monoclonal antibody that increases antitumor T-cell responses. We conducted a meta-analysis of randomized controlled trials (RCTs) to evaluate the risk of FAEs associated with ipilimumab. METHODS: We searched PubMed, EMBASE, and ASCO meeting abstract up to September 2016 for RCT comparing ipilimumab with no ipilimumab on cancer patients. Incidence rates, relative risk ratios (RRs), and 95% confidence intervals (CIs) were calculated using fixed- or random effects models...
February 24, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28263392/risk-of-hepatotoxicity-in-cancer-patients-treated-with-immune-checkpoint-inhibitors-a-systematic-review-and-meta-analysis-of-published-data
#18
Wenjun Wang, Puyi Lie, Minzhang Guo, Jianxing He
AIMS: Although existing evidence from clinical trials has demonstrated manifestation of hepatic adverse events with the use of immune checkpoint inhibitors (ICPIs), overall risks have yet to be reported. Therefore, we assessed the risk of hepatotoxicity associated with inhibitors of the immune checkpoint Materials and methods: We examined data from the Pubmed, Medline and Google Scholar databases. We also examined original studies and review articles for crossreferences Eligible studies included randomised phase II to phase III trials of cancer patients treated with nivolumab, pembrolizumab, ipilimumab, tremelimumab...
March 6, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28259284/pembrolizumab-s-non-cross-resistance-mechanism-of-action-successfully-overthrown-ipilimumab
#19
REVIEW
Mohd Wahid, Naseem Akhter, Arshad Jawed, Sajad A Dar, Raju K Mandal, Mohtashim Lohani, Mohammed Y Areeshi, Saif Khan, Shafiul Haque
The incidences of melanomas are increasing by leaps and bounds across the globe despite early detection and intervention. The numbers of patients dying from metastatic melanoma have been continually increased over the past thirty years. It has been considered as one of the most therapy-resistant malignancies due to the cross-resistant mechanism developed by the metastatic cells. With time, many new therapies came and they failed miserably. Ipilimumab, a monoclonal antibody that works to activate the immune system by targeting CTLA-4 proved to be a boon for advance melanoma very recently...
March 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28257394/reinduction-of-pd1-inhibitor-therapy-first-experience-in-eight-patients-with-metastatic-melanoma
#20
Hanna Blasig, Carolin Bender, Jessica C Hassel, Thomas K Eigentler, Michael M Sachse, Julia Hiernickel, Anika Koop, Imke Satzger, Ralf Gutzmer
Significant progress has been made in the treatment of metastatic melanoma during the last years. Approval of immune-checkpoint inhibitors and targeted therapies has been achieved recently. The sequencing of these therapies is an important issue. Here, we report our experience with the treatment and retreatment with PD1-inhibitors (PD1i) in eight patients. The patients (two female and seven male with a median age of 70 years, all melanoma stage IV, M1c) underwent a first treatment period with PD1i for a median of 5...
March 2, 2017: Melanoma Research
keyword
keyword
10967
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"